Search
Now showing items 1-7 of 7
Developing standards of care for HIV prevention research in developing countries – a case study of ten research centers in Eastern and Southern Africa
(2012-09)
Background:
Standards of care in general vary across countries and communities and thus may affect decisions about standards of care provided by research centers in HIV prevention research. To serve as a basis for ...
Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth.
(2012)
To identify and describe populations at risk for HIV in 3 clinical research centers in Kenya and South Africa.
DESIGN:
Prospective cohort study.
METHODS:
Volunteers reporting recent sexual activity, multiple partners, ...
Mucosal specimen collection, processing and assay - Experience from a resource-limited setting in Kenya
(University of Nairobi, 2013)
Background:
HIV-1 infection occurs most commonly through
sexual intercourse. Induction of mucosal immune responses will
likely be necessary for an effective HIV vaccine. KAVI embarked
on building capacity for mucosal ...
HIV-1 viral control varies by viral subtype in a large cohort of African adults with incident HIV-1 infection.
(Oxford Academic, 2019-04-02)
Few HIV-infected persons can maintain low viral levels without therapeutic intervention. We evaluate predictors of spontaneous viral control in a prospective cohort of African adults shortly after HIV infection. Viral ...
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
(2014)
A qualitative assessment of Kenyan men who have sex with men taking daily and intermittent oral HIV pre-exposure prophylaxis (PrEP) found stigma, sex work, mobility, and alcohol impacted adherence. We analyzed quantitative ...
Broad HIV-1 inhibition in vitro by vaccine-elicited cd8(+) t cells in African adults.
(University of Nairobi, 2016)
We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally ...
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
(Oxford Academic, 2019-06-05)
BACKGROUND:
During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and ...